Generate Biomedicines, Inc. Common Stock (GENB) — Financial Flexibility Index
Generate Biomedicines, Inc. Common Stock (GENB) has a Financial Flexibility Index of -0.21x as of December 2025. Free cash flow of $-197.10 Million (operating CF $-200.62 Million minus capex $3.51 Million) represents 0% of total liabilities ($953.38 Million). Also explore net asset momentum of Generate Biomedicines, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Generate Biomedicines, Inc. Common Stock Financial Flexibility Index (2024–2025)
Historical Financial Flexibility Index trend for Generate Biomedicines, Inc. Common Stock across 2 annual periods. Check Generate Biomedicines, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Annual Financial Flexibility Index for Generate Biomedicines, Inc. Common Stock (2024–2025)
Year-by-year free cash flow to debt coverage for Generate Biomedicines, Inc. Common Stock. For the full company profile including market capitalisation, see GENB stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.21x | $-197.10 Million | $-200.62 Million | $953.38 Million | ▼ -72.4% |
| 2024 | -0.12x | $-114.30 Million | $-117.75 Million | $953.35 Million | — |